A practical reference on Alpha-MSH: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
These data show that the standard enthalpy changes are indeed approximately equal for the two reactions and that the main reason why the chelate complex is so much more stable is that the standard entropy term is much less unfavourable, indeed, it is favourable in this instance. In general it is difficult to account precisely for thermodynamic values in terms of changes in solution at the molecular level, but it is clear that the chelate effect is predominantly an effect of entropy. Other explanations, including that of Schwarzenbach, are discussed in Greenwood and Earnshaw.
=== Biosphere === Methanogenesis is a form of anaerobic respiration used by microbes, and microbial methanogenesis can occur in deep subsurface, marine sediments, freshwater bodies, etc. It appears that methane from deep subsurface and marine sediment is generally in internal isotopic equilibrium., while freshwater microbial methanogenesis expresses large kinetic isotope effect on methane clumped isotope composition. There are two possible explanations for this variance: firstly, substrate limitation may enhance the reversibility of methanogenesis, thus allowing methane to achieve internal isotopic equilibrium via rapid hydrogen exchange with water; secondly, activation of C-H bonds during anaerobic oxidation precedes reversibly such that C-H bonds are broken and reformed faster than the net rate of methane consumption and methane can be reequilibrated.
== Further reading == Melik, James (8 July 2009). "Danone's yogurt strategy for Bangladesh". BBC. Kiviat, Barbara (23 August 2010). "Danone's Cheap Trick". Time. Faizul Latif Chowdhury : "The Business of 'Social Business'", The New Age, Dhaka.
Sources: en.wikipedia.org
rescue The restoration of a defective cell or tissue to a healthy or normal condition, or the reversion or recovery of a mutant gene to its normal functionality, especially in the context of experimental genetics, where an experiment (e.g. a drug, cross, or gene transfer) resulting in such a restoration is said to rescue the normal phenotype.
=== Non-human models === Azvudine is found to be mutagenic in in vitro in the Ames test, CHL test, and in vitro in the mice micronucleus test. Azvudine is toxic to the reproductive system of rats and rabbit. The minimum reproductive NOAEL found for males is 5.0 mg/kg/d and for females 0.5 mg/kg/d. It is excreted in rat breast milk; the NOAEL for rat pups is 1.5 mg/kg/d. Azvudine is mainly toxic to the immune system, bone marrow, and digestive system of model animals. The chronic NOAELs are 0.5 mg/kg/d (rat, 3 months), 0.3 mg/kg/d (rat, 26 weeks), and 0.1 mg/kg/d (beagle dog, 1 month and 39 weeks). For comparison, the chronic human dose for HIV treatment is 0.05 mg/kg/d, using the reference 3 mg dose and an average Chinese body mass of 59.5 kg (2014).
=== 7 July === Russian forces claimed to have taken the settlement of Chyhari (part of Pivdenne) in Donetsk Oblast. Four people were killed after their vehicle struck a Russian-planted mine in Kharkiv Oblast. Russian officials claimed that Iskander ballistic missiles destroyed two Patriot missile launchers in Odesa. The Ukrainian Air Force confirmed the attack but provided no further information. The Ukrainian military claimed to have shot down a Russian Su-25 fighter jet over Donetsk Oblast. Russian officials claimed that falling debris from Ukrainian drones set fire to a warehouse in Voronezh Oblast which contained explosives. Another drone was reported shot down over Belgorod Oblast. Explosions were reported at a number of locations around occupied Melitopol, including the Melitopol Air Base, the railway station and other areas. Locals said that Russian air defence was activated during the incident.
Sources: en.wikipedia.org
Significant flooding is reported in Ōkato, Egmont Village, New Zealand State Highway 3, and Eltham. New Plymouth's sewage system is also inundated. 4 July – Defence Minister Judith Collins announces the reactivation of No. 62 Squadron RNZAF as the New Zealand Defence Force's first dedicated space force unit. 10 July – Civil defence authorities declare a pre-emptive state of emergency in Nelson-Tasman in response to MetService's orange heavy rain warning for the region. 11 July: A 14-year-old boy is sentenced to three years and three months in prison for the killing of Enere McLaren-Taana. MetService issues a red heavy rain warning in parts of the Tasman District in response to heavy rain and flooding. 100 homes are evacuated due to flooding. MetService also issues orange heavy rain warnings in the Northland Region, Auckland Region, Waikato and Coromandel Peninsula. 12 July — MetService lifts weather warnings for much of the country except the Westland ranges. Hundreds of households in the Tasman District and Banks peninsula experience weather-related power cuts. 15 July — The Commerce Commission files civil proceedings against Foodstuffs North Island and its subsidiary Gilmours for alleged cartel conduct. 16 July — Education Minister Erica Stanford announces that the New Zealand Government will be ending open-plan class rooms in favour of single-cell classrooms. 18 July — The Gore District Council issues a directive not to drink tap water in Gore due to high nitrate levels.
=== Doctoral students === His doctoral students at the University of California included Roy Elwood Clausen, Carl L. A. Schmidt, and Selman Waksman (the 1952 Nobel Prize in Physiology or Medicine for the discovery of streptomycin).
== Career == Parsons developed strong musical interests early in life, particularly after seeing Elvis Presley perform in concert in Waycross, on February 22, 1956. Five years later, he was playing in rock and roll cover bands such as the Pacers and the Legends, headlining in Winter Haven/Polk County clubs owned by his stepfather. By age 16, he had graduated to folk music, and in 1963 he teamed up with his first professional outfit, the Shilohs. Heavily influenced by The Kingston Trio and The Journeymen, the band played hootenannies, coffee houses and high school auditoriums; as Parsons was still enrolled in prep school, he performed with the group only in select engagements. Forays into New York City included a performance at Florida's exhibition in the 1964 New York World's Fair and regular appearances at the Café Rafio on Bleecker Street in Greenwich Village in the summer of 1964. Although John Phillips (an acquaintance of Shiloh George Wrigley) arranged an exploratory meeting with Albert Grossman, the impresario balked at booking the group for a Christmas engagement at The Bitter End when he discovered that the Shilohs were high school students. Following a recording session at the radio station of Bob Jones University, the group reached a creative impasse amid the emergence of folk rock and dissolved in the spring of 1965.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.